E-Mail:Tamary@hadassah.org.il

Marital Status: Married, 2 children

Military Service: 1970 – 1972

Nationality: Israeli

Education

1966-1970  Tichon Chadash High School, Tel Aviv, Israel

1973-1979  HebrewUniversity – Hadassah Medical School, Jerusalem, Israel

1980  MD Degree, Hebrew University – Hadassah Medical School

Academic Affiliation

Hebrew University – Hadassah Medical School

Oct. 1996  Associate Professor in Oncology

Apr. 1992  Senior Lecturer in Oncology

Apr. 1986  Lecturer in Oncology

Oct. 1982  Instructor in Oncology

Positions

Nov. 1994 -present Head, Sharett Institute of  Oncology, Hadassah University Hospital, Jerusalem.

July 1993 – Oct. 1994  Acting Head,  Sharett Institute of Oncology

Feb. 1990 – July 1991 In charge of Oncology Outpatient Clinic, Hadassah University Hospital

Nov. 1989 – May1990  Acting Head, Brachytherapy Unit, Hadassah University Hospital

1988 – 1989  Research Fellow, Surgical Metabolic Lab headed by M.F. Brennan, Chairman Dept of Surgery, Memorial Sloan-Kettering Cancer Center, NewYork

1987 – 1988  Fellow in Brachytherapy and Radiotherapy, Dept of Radiation Oncology, Memorial Sloan-Kettering Cancer Center

1986 – 1994 Attending Physician (on staff),  Dept of Oncology, Hadassah University Hospital

1981 – 1986 Residency in Radiation and Medical Oncology, Dept of Oncology,  Hadassah University Hospital

1980  Rotating Internship, Hadassah University Hospital

Medical Societies

·         Israel Medical Association

·         Israeli Society of Oncology

·         Israel Society for Medicine and Law

·         Israeli Society for Surgical Oncology

·         The Israeli Menopause Society

·         The Israeli Society of Breast Diseases

·         Israeli Society of Women Physicians

·         American Society of Radiation Oncology

·         The Middle East Cancer Society

·         The American Association for Cancer Research

·         European Society of Mastology

·         European Society for Medical Oncology

·         The European Senology Society

·         European Society of Cancer Research

·         American Society of Clinical Oncology

·         The American Society of Breast Diseases

·         New York Academy of Science

·         The American Association for the Advancement of Science

·         The New York Hospital-Cornell Medical Center Alumni Council

·         The Memorial Hospital Alumni Society

Professional Activities

Board of  Directors, Israel Cancer Society.

Guest Editor, Israel Journal of Medical Science (Special issue in memory of Prof Shoshana Biran)

Editorial Board, IMAJ (Israeli Medical Association Journal)

Member of Research Committee, Israel Cancer Society

Member of Research Committee, Israeli Society of Surgical Oncology

Member of The Central Committee, The Israeli Society of Breast Diseases

Member of Audit Committee, Israeli Oncology Society

Former Member of The Health Committee, Israeli Women’s Network

Former Member of The Advisory Committee for Women’s Health, Israel Ministry of Health

Member of The National Oncology Council

Member of The Committee for Approval of New Drugs, Israel Ministry of Health

Former Member of The Committee for Clinical Trials, Israel Ministry of Health

Board of Directors, The Natural Step

Life Member, Hadassah Women’s Organization

Invited expert witness in courts

Examinations

1979 - VQE Visa Qualifying Examination for Foreign Medical Graduates – passed

1984 - Board Exam in Radiation and Medical Oncology, Stage I

1985 - Board Exam in Radiation and Medical Oncology, Stage II

1988 - FLEX Exam in New York State

Awards

1978 – 1979  Medical School Scholarship for Excellence

Research Grants

Joint Research Fund of the Hebrew University and Hadassah University Hospital.  Growth pattern of primary carcinoma of the ovary on extracellular matrix: response to hormones and effects of chemotherapeutic agents (1984).

Israel Cancer Association.  Denial and adjustment to cancer of colon patients and their spouses (1986).

Joint Grant of the Hebrew University and Hadassah University Hospital.  Growth pattern of primary carcinoma of the ovary on extracellular matrix:  response to hormones and effects of chemotherapeutic agents (1986).

Israel Cancer Association.  Holocaust-survivor cancer patients:  the influence of severe past trauma on coping ability with a new trauma (1988-1989).

Israel Cancer Association.  Treatment by imaginary and guided relaxation in holocaust survivors with cancer (1990).

Israel Cancer Research Foundation.  Gender of patients and spouses and adjustment to cancer (1990-1991).

Joint Grant of the Hebrew University and Hadassah University Hospital Evaluating the role of growth factors in cancer-associated metabolic changes (1990).

Joint Grant of the Hebrew University and Hadassah University Hospital (Claire Shunloch Fund for Cancer Research).  Weight low resulting from cancer – research on the mechanisms and development of means to overcome (control) this phenomenon (1991-1992).

Chief Scientist, Israel Ministry of Health.  Evaluating the role of growth factors in tumor-induced metabolic alterations (1992).

Israel Women's Network.  Breast Cancer among ultra orthodox women (1994-1995).

Israel Cancer Association.  Genetic changes in pre-neoplastic breast tissue (1994-1995).

Joint Grant of the Hebrew University and Hadassah University Hospital.  Development of a new approach for the receptor-mediated transfer of cytokine genes-antigenes complexes (1998).

THMRF Grant.  Targeting the transcriptional factor AP-2 for the treatment of breast cancer (with Prof. I. Vlodavsky and Dr. R. Reich) (1999).

Horowitz Foundation.  Dendritic cell-based vaccinations against melanoma:  preclinical studies and clinical phase I/II trials (with S. Frankenburg and M. Lotem) (1999-2002).

MECC (Mediterranean Cancer Consortium, NCI supported).  Screening for BRCA-1 BRCA-2 mutations in Palestinian women with breast cancer (1999-2001),

The Institutional Women's Health Grant Foundation.  Effects of Isoflavones (Phytoestrogens) on dysplastic and malignant epithelial breast cells in vitro (with A. Brzezinski et al.) (2000).

The Institutional Women's Health Grant Foundation.  BRCA mutation carriers:  factors influencing them to have preventive surgery and to transfer the information to relatives (with M. Sagi) (2000).

The Institutional Women's Health Grant Foundation.  Cardiac dysfunction post herceptin therapy in women with breast cancer (2001-2002).

The Institutional Women's Health Grant Foundation.  In search of characteristic immunophenotype for BRCA-1 and BRCA-2 related breast cancer (2001-2002).

Sylvia and David Salzberg Cancer Research Fund.  Involvement of heparanase in ovarian carcinoma progression (2001-2002).

Edmond and Nadine de Rothschild Foundation.  Early detection of breast cancer in weak populations in Jerusalem (2001-2002).

Israel Cancer Association.  Final results of a prospective randomized trial comparing 5-Flourouracil with Leucovorin to 5-Flouracil with Levamisole as adjuvant therapy of colorectal cancer – The Israel Cooperative Oncology Group Study (with A. Nissan et al.) (2002-2003).

Papers in Peer Reviewed Journals (1996-2004)

1. Baider L, Peretz T, and Kaplan De-Nour A: The effect of behavioral intervention on the psychological distress of holocaust survivors with cancer. Psychotherapy and Psychosomatics. 66: 44-49, 1997.

2. Abeliovich D, Kadouri L, Lerer I, Weinberg N, Amir G, Sagi M, Zlotogora J, Heching NI, and Peretz T: The founder mutation 185delAG and 5382insC in BRCA-1 and 6174delT in BRCA-2 appear in 60% of ovarian cancer and 30% of  early-onset breast cancer patients among Ashkenazi women.  American J. Human Genetics.  60: 505-514, 1997.

3. Peretz T, Kaplan De-Nour A, Baider L, Hubert A, Stephanos S, Barak V: The combination of interferon and tamoxifen for patients with advanced breast cancer and negative estrogen receptors. The Breast. 6: (4) 190-193, 1997.

4. Metzger S, Goldschmidt N, Barash V, Peretz T, Drize O, Shilyansky J, Shiloni E, and Chajek-Shaul T: Interleukin-6 secretion in mice is associated with reduced glucose-6- phosphatase and liver glycogen levels. Am J. Physiol. 273: E 262-267,  1997. Nisman B, Lafair J, Heching NI, Lyass O, Baras M, Peretz T, Barak V: Evaluation of tissue polypeptide specific antigen CYFRA 21-1, and carcino-embryonic antigen in non small cell lung carcinoma. Cancer. 15: 82 (10) 1850-9, 1998.

5. Nisman B, Lafair J, Heching NI, Lyass O, Baras M, Peretz T, Barak V: Evaluation of tissue polypeptide specific antigen CYFRA 21-1, and carcino-embryonic antigen in non small cell lung carcinoma. Cancer. 15: 82 (10) 1850-9, 1998.

6. Metzger S, Begleibter N, Barash V, Drize O, Peretz T, Shiloni E, and Chajek- Shaul T: Tumor necrosis factor inhibits the transcriptional rate of glucose-6-phosphatase in vivo and in vitro. Metabolism. 46: (5) 579-83, 1997.

7. Barak V, Nisman B, Roisman I, Hubert A, Farbstein H, Kaplan A, Halperin T, Stephanos S, Peretz T: Tps in assessing response to therapy and prognosis of breast cancer patients treated with interferons. J. Tumor Marker Oncology. 12: (4) 17-26, 1997.

8. Lerer I, Wang T, Peretz T, Sagi M, Kadouri L, Orr-Urtreger A, Stadler J, Gutman H, Abeliovich D: The 8765delAG mutation in BRCA2 is common among Jews of Yemenite extraction: Am. J. Hum. Genet. 63: 272-274, 1998.

9. Friedman  E, Bar-Sade B, Kruglikova A, Risel S, Levy-Lahad E, Halle D, Bar-On E, Gershoni- Baruch R, Dagan E, Kepten I, Peretz T, Lerer I, Weinberg N, Shushan  A, and  Abeliovich D:  Double heterozygotes for the Ashkenazi founder mutations in BRCA1 and BRCA2 genes. Am J Hum Genet.  63: (4) 1224-7, 1998.

10. Barak V, Kalickman I, Nisman B, Farbstein H, Fridlender ZG, Baider L, Kaplan De-Nour A, Stephanos S, and Peretz T: Changes in cytokine production of breast cancer patients treated with interferons. Cytokine. 10: (12), 977-983, 1998.

11. Sagi M, Kadouri L, Zlotogora J, and Peretz T: The effect of genetic counseling on knowledge and perceptions regarding risks for breast cancer. Journal of Genetic Counseling.  7:%

12. Hubert A,  Peretz T, Manor O, Kadouri L, Weinberg N, Lerer I, Sagi M and  Abeliovich D: The Jewish Ashkenazi founder mutations in the BRCA1/2 genes are not found at an increased  frequency in prostate cancer Ashkenazi patients.  Am J Human Genet.  65: (3), 921-924, 1999.

13. Kadouri L, Gips  M, Hubert A, Sagi M, Heching N, Lerer I, Uziely B, Weinberg N, Abeliovich D,  Peretz T: Genetic testing of breast and ovarian cancer patients: clinical characteristics and hormonal risk modifiers.  European Journal of Obstetrics & Gynecology and Reproductive Biology.   85: 75-80,1999.

14. Nisman B,  Amir G,  Lafair  J, Heching  NI, Lyass O,  Peretz T, and  Barak V: Prognostic value of Cyfra 21-1, TPS and  CEA in  different histologic types of non small cell lung cancer. Anticancer Research. 19: (4C) 3549-3552, 1999. 

15. Baider L, Peretz T, Ever-Hadani P, Perry S, Avramov R, and  Kaplan De-Nour A: Transmission of response to trauma? Second generation holocaust survivors'  reaction to cancer. Am J Psychiatry. 157: (6) 904-910, 2000.

16. Peretz T, Weshler Z, Goldberg Y, Durst AL, and Freund HR: Brief  preoperative radiotherapy reduces local recurrences and improves survival in rectal cancer.  Harefuah. 16: 138 (2),  96-99, 2000. (Hebrew).

17. Friedmann Y, Vlodavsky I, Aingorn H, Aviv A, Peretz T, Pecker I, Pappo O: Expression of Heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol. 157: (4) 1167-75, 2000.

18. Barak V, Nisman B, Hubert A, Lyass O, Kadouri L, Peretz T:  Prognostic Efficacy of TPS in Breast Cancer. J Tumor Marker Oncology. 15: (3) 171-176, 2000.

19. Wang T, Lerer I, Gueta Z, Sagi M, Kadouri L, Peretz T, and Abeliovich D: A deletion/insertion mutation in the BRCA1/2 gene in a breast cancer family: A possible  role of the Alu-polyA tail in the evolution of the deletion genes. Genes, Chromosomes and Cancer, 31: 91-95, 2001

30. Klein M, Weininger  J, Moshe S, Peretz T, and Chisin R: The use of external radioactive markers in scintimammography.  Clinical Nuclear Medicine.  26: (1), 10-13, 2001.

31. Paltiel O, Avitzour T, Peretz T,  Cherny N,  Kadouri L, Pfeffer RM, Wagner N, and Soskolne V: Determinants of the use of complementary therapies by cancer patients.  Journal of Clinical Oncology. 19: (9), 2439-2448, 2001.

32. Kadouri L,  Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T, and Eeles RA: CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. British Journal of Cancer. 85: (1), 36-40, 2001. 

33. Manning AP, Abeliovich D, Ghadirian P, Lambert JA, Frappier D, Provencher D, Robidoux A, Peretz T, Narod SA, Mes-Masson A.M, Foulkes WD, Wang T, Morgan K, Fujiwara TM, and Tonin PN:  Haplotype analysis of BRCA2  8765delAG  mutation carriers in French Canadian and Yemenite Jewish hereditary breast cancer families. Hum Hered. 52: (2), 116-120, 2001.

34. Baider L, Peretz T, Ever-Hadani P, Koch U:  Psychological intervention in cancer patients:  a randomized study. Gen Hosp Psychiatry. 23: (5) 272-277, 2001.

35. Thompson D, Szabo CI, Mangion J, Oldenburg RA, Odefrey F, Seal S, Barfoot R, Kroeze-Jansema K, Teare D, Rahman N, Renard H, KConFab Consortium, Mann G, Hopper JL, Buys SS, Andrulis IL, Senie R, Daly MB, West D, Ostrander EA, Offit K, Peretz T, Osorio A, Benitez J, Nathanson KL, Sinilnikova OM, Olah E, Bignon YJ,  Ruiz P, Badzioch MD, Vasen HF, Futreal AP, Phelan CM, Narod SA, Lynch HT,  Ponder BA, Eeles RA, Meijers-Heijboer H, Stoppa-Lyonnet D, Couch FJ, Eccles DM, Evans DG, Chang-Claude J, Lenoir G, Weber BL, Devilee P, Easton DF, Goldgar DE,  Stratton MR.: From the Cover: Evaluation of linkage of breast cancer to the putative BRCA3 locus on chromosome 13q21 in 128 multiple case families from the Breast Cancer Linkage Consortium. Proc Natl Acad Sci USA. 22;99(2):827-831, 2002.

36. Tanos V, Brzezinsky A, Drize O, Strauss N, Peretz T: Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol. 102: (2), 188-194, 2002.

37. Lotem M, Peretz T, Drize O, Gimmon Z, Ad El D, Weitzen R, Goldberg H, Ben David I, Prus D, Hamburger T, Shiloni E: Autologous cell vaccine as a post operative adjuvant treatment for high-risk melanoma patients (AJCC stages III and IV). British Journal of Cancer  86, 1534-1539, 2002.

38. Nisman B, Barak V, Shapiro A, Golijanin D, Peretz T, Pode D:  Evaluation of urine Cyfra 21-1 for the detection of  primary and recurrent bladder carcinoma. Cancer 94 (11) 2914-2922, 2002.

39. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar Shira A, Soloviov S, Schreiber L, Matzkin H, Rennert G, Kadouri L, Peretz T, Yaron Y, Orr Urtreger  A:  A Novel Founder Mutation in the RNASEL Gene, 471delAAAG, is Associated with Prostate Cancer in Ashkenazi Jews.  Am J Hum Genet, 2002.

40. Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, Elstrodt F, van Duijn C, Bartels C, Meijers C, Schutte M, McGuffog L, Thompson D, Easton D, Sodha N, Seal S, Barfoot R, Mangion J, Chang-Claude J, Eccles D, Eeles R, Evans DG, Houlston R, Murday V, Narod S, Peretz T,  Peto J, Phelan C, Zhang HX, Szabo C, Devilee P, Goldgar D, Futreal PA, Nathanson KL, Weber B, Rahman N, Stratton MR:  Low penetrance susceptibility to breast cancer due to CHEK2(*%).